Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 12/20 | 0.58 |
| ▸ | PTK2B | Q14289 | 9/20 | 0.51 |
| ▸ | FLT3 | P36888 | 4/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | BMX | P51813 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL579013 | 0.99 | PTK2 (0.60) | PTK2PTK2BFLT3KITAURKA | |
| SCHEMBL579014 | 0.99 | PTK2 (0.60) | PTK2PTK2BFLT3KITAURKA | |
| SCHEMBL4196615 | 0.93 | PTK2 (0.55) | PTK2PTK2BFLT3KITAURKA | |
| SCHEMBL13808216 | 0.92 | PTK2 (0.54) | PTK2PTK2BFLT3KITAURKA | |
| SCHEMBL578904 | 0.92 | PTK2 (0.57) | PTK2PTK2BFLT3KITAURKA | |
| SCHEMBL579202 | 0.92 | PTK2 (0.56) | PTK2PTK2BFLT3KITAURKA | |
| SCHEMBL13808112 | 0.92 | PTK2 (0.55) | PTK2PTK2BFLT3KITAURKA | |
| SCHEMBL579144 | 0.91 | PTK2 (0.57) | PTK2PTK2BFLT3KITAURKA | |
| SCHEMBL579114 | 0.91 | PTK2 (0.57) | PTK2PTK2BFLT3KITAURKA | |
| SCHEMBL13808111 | 0.91 | PTK2 (0.56) | PTK2PTK2BFLT3KITAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623887-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623887-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20130289014-A1 | Combination therapy in treatment of oncological and fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20120107304-A1 | Combination therapy in treatment of oncological and fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20090163467-A1 | New compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163467-A1 | New compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107304-A1 | Combination therapy in treatment of oncological and fibrotic diseases | AURKB, AURKC, AURKA | PTK2 35/4885PTK2B 98/4885FLT3 235/4885 |
| US-20130289014-A1 | Combination therapy in treatment of oncological and fibrotic diseases | AURKB, AURKC, AURKA | PTK2 35/4885PTK2B 98/4885FLT3 235/4885 |
| US-20090163467-A1 | New compounds | CCNA1, MKI67, CCNT1 | PTK2 1550/4885PTK2B 2309/4885FLT3 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.